Abstract 114P
Background
Pathogenic or likely pathogenic germline variants (PGVs) in cancer predisposition genes may play a role in lung cancer (LC) susceptibility. However, determining an eligible population for genetic testing remains uncertain. This study aimed to assess the prevalence of PGVs in a selected cohort of individuals with lung adenocarcinoma.
Methods
A cross-sectional cohort study was conducted to assess PGVs rate in lung adenocarcinoma patients with a family history of LC, young-onset presentation, history of never/light smoking, or actionable genomic alterations (AGAs). Sequencing was performed using Sophia Hereditary Cancer Solution panel F, including 144 cancer predisposition genes. Variants classified as pathogenic or likely pathogenic were included for further analysis.
Results
We incluided 201 patients, of which 43 (21.4%) exhibited PGVs, identifying that 64.5% occurred in DNA damage repair genes, being 86.1% clinically actionable. The most frequent PGVs were found in ATM (9.3%), TP53 (6.9%), BRCA2 (6.9%), and CHEK2 (6.9%) genes. PGVs were associated with male sex (adjusted odds ratio [aOR] 2.54, 95% CI 1.17–5.53, p=0.019), very young-onset presentation (aOR 5.79, 95% CI 1.35–24.74, p=0.018), and first-degree relatives with LC (aOR 3.78, 95% CI 1.11–12.83, p=0.033), along with a trend toward association with AGAs (aOR 6.42, 95% CI 0.79–52.18, p=0.082).
Conclusions
This study identified a high PGVs prevalence based on our selection criteria, thus representing an effective strategy to select candidates for germline genomic testing, potential screening strategies in close relatives, and personalized therapeutic modalities. Our results warrant further exploration in other populations to confirm them.
Clinical trial identification
NCT06181812.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
This study was supported by CONAHCyT (A3-S-47960) and Becas Impulso a La Investigación En Salud “Carlos Slim” 2023 (N20230149).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
173P - Unveiling a novel EpCAM-CD24+ circulating cells with unidentified origin associated with breast cancer distant metastasis
Presenter: Evgeniya Grigoryeva
Session: Poster session 08
174P - Prognostic value of the immune and metabolic profile in the response to neoadjuvant treatment with ICIs in triple-negative breast cancer patients (TNBC)
Presenter: Lucía Serrano García
Session: Poster session 08
175P - Utility of artificial intelligence (AI) in Ki67 scoring of a breast cancer (BC) patient population
Presenter: Xavier Pichon
Session: Poster session 08
176P - ERBB2 amplifications across sex, race, and cancer types
Presenter: Marc Machaalani
Session: Poster session 08
177P - HER2 testing in multiple solid tumors: Concordance between 3 scoring algorithms
Presenter: Wentao Yang
Session: Poster session 08
178P - PD-L1 expression in ER-low versus triple-negative (TN) advanced breast cancer (aBC), and according to phenotypic evolution from primary to recurrent disease
Presenter: Federica Miglietta
Session: Poster session 08
179P - Multimodal deep learning integrating MRI and molecular profiles for predicting outcomes in triple-negative breast cancer
Presenter: Seong Hwan Park
Session: Poster session 08
181P - Molecular characterization and immune microenvironment analysis of MSI-H patients with or without MMR gene mutations
Presenter: Mengxi Ge
Session: Poster session 08
182P - Multi-modal artificial intelligence outperforms image-based approaches for mutation prediction from H&E tissue images in colorectal cancer
Presenter: Marc Päpper
Session: Poster session 08